Dexamethasone nanomedicines for COVID-19

Twan Lammers; Alexandros Marios Sofias; Roy van der Meel; Raymond M. Schiffelers; Gert Storm; Frank Tacke; Steffen Koschmieder; Tim H. Bruemmendorf; F. Kiessling; Josbert M. Metselaar

doi:10.1038/s41565-020-0752-z

Dexamethasone nanomedicines for COVID-19

Twan Lammers (Corresponding author)
, Alexandros Marios Sofias
, Roy van der Meel
, Raymond M. Schiffelers
, Gert Storm
, Frank Tacke
, Steffen Koschmieder
, Tim H. Bruemmendorf
, F. Kiessling
, Josbert M. Metselaar (Corresponding author)

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

161 Citations (Scopus)

65 Downloads (Pure)

Abstract

Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

Original language	English
Pages (from-to)	622-624
Number of pages	3
Journal	Nature Nanotechnology
Volume	15
Issue number	8
DOIs	https://doi.org/10.1038/s41565-020-0752-z
Publication status	Published - 3 Aug 2020

Funding

Funders	Funder number
European Union's Horizon 2020 - Research and Innovation Framework Programme	864121
European Union's Horizon 2020 - Research and Innovation Framework Programme
Deutsche Forschungsgemeinschaft	331065168

Access to Document

10.1038/s41565-020-0752-z

publisher versionFinal published version, 5.28 MBLicence: TAVERNE

Cite this

@article{69c5d7ca30bd4d1da0063abbec7b3284,

title = "Dexamethasone nanomedicines for COVID-19",

abstract = "Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.",

author = "Twan Lammers and Sofias, \{Alexandros Marios\} and \{van der Meel\}, Roy and Schiffelers, \{Raymond M.\} and Gert Storm and Frank Tacke and Steffen Koschmieder and Bruemmendorf, \{Tim H.\} and F. Kiessling and Metselaar, \{Josbert M.\}",

year = "2020",

month = aug,

day = "3",

doi = "10.1038/s41565-020-0752-z",

language = "English",

volume = "15",

pages = "622--624",

journal = "Nature Nanotechnology",

issn = "1748-3387",

publisher = "Nature Research",

number = "8",

}

TY - JOUR

T1 - Dexamethasone nanomedicines for COVID-19

AU - Lammers, Twan

AU - Sofias, Alexandros Marios

AU - van der Meel, Roy

AU - Schiffelers, Raymond M.

AU - Storm, Gert

AU - Tacke, Frank

AU - Koschmieder, Steffen

AU - Bruemmendorf, Tim H.

AU - Kiessling, F.

AU - Metselaar, Josbert M.

PY - 2020/8/3

Y1 - 2020/8/3

N2 - Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

AB - Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.

UR - https://www.scopus.com/pages/publications/85088866461

U2 - 10.1038/s41565-020-0752-z

DO - 10.1038/s41565-020-0752-z

M3 - Comment/Letter to the editor

C2 - 32747742

SN - 1748-3387

VL - 15

SP - 622

EP - 624

JO - Nature Nanotechnology

JF - Nature Nanotechnology

IS - 8

ER -

Dexamethasone nanomedicines for COVID-19

Abstract

Funding

Access to Document

Other files and links

Fingerprint

Cite this